6 assets in Hyper-IgM Syndrome Type 1

Therapeutic assets addressing Hyper-IgM Syndrome Type 1, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Alemtuzumab Hyper-IgM Syndrome Type 1	Paul Szabolcs	P2	CCC (53)
Cyclophosphamide Hyper-IgM Syndrome Type 1	Roswell Park Cancer Institute	P2	CCC (53)
Fludarabine Hyper-IgM Syndrome Type 1	Paul Szabolcs	P2	CCC (53)
Melphalan Hyper-IgM Syndrome Type 1	Paul Szabolcs	P2	CCC (53)
Busulfanum Hyper-IgM Syndrome Type 1	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Mesna Hyper-IgM Syndrome Type 1	Masonic Cancer Center, University of Minnesota	N/A	D (30)